[1]毛礼阳 邵春阳.尼莫地平联合尼麦角林治疗阿尔茨海默病患者的效果及对血清E2、HIF-1α水平的影响[J].卒中与神经疾病杂志,2019,26(03):313-316.[doi:10.3969/j.issn.1007-0478.2019.03.013]
　Mao Liyang*,Shao Chunyang. *.The clinical effect of nimodipine combined with niergoline on patients with Alzheimer's disease and its effect on serum E2 and HIF-1α alpha levels[J].Stroke and Nervous Diseases,2019,26(03):313-316.[doi:10.3969/j.issn.1007-0478.2019.03.013]
点击复制

尼莫地平联合尼麦角林治疗阿尔茨海默病患者的效果及对血清E2、HIF-1α水平的影响()
分享到：

《卒中与神经疾病》杂志[ISSN:1007-0478/CN:42-1402/R]

卷:
第26卷
期数:
2019年03期
页码:
313-316
栏目:
论 著
出版日期:
2019-06-25

文章信息/Info

Title:
The clinical effect of nimodipine combined with niergoline on patients with Alzheimer's disease and its effect on serum E2 and HIF-1α alpha levels
文章编号:
1007-0478(2019)03-0313-04
作者:
毛礼阳 邵春阳
225261 江苏省扬州友好医院内二科(毛礼阳),检验科(邵春阳)
Author(s):
Mao Liyang*;  Shao Chunyang. *
Second Department of Medicine, Yangzhou Friendship Hospital, Yangzhou 225261
关键词:
尼莫地平 尼麦角林 老年性痴呆 雌激素 低氧诱导因子-1α
Keywords:
Nimodipine Niergoline Alzheimer's disease E2 HIF-1α
分类号:
R742
DOI:
10.3969/j.issn.1007-0478.2019.03.013
文献标志码:
A
摘要:
目的 观察尼莫地平联合尼麦角林对于阿尔茨海默病患者的临床效果及其对患者血清中雌激素(E2)、低氧诱导因子-1α(HIF-1α)水平的影响。方法 选取2015年6月-2018年3月于本院住院治疗的AD患者138例,按照随机数字表法分为对照组和观察组; 对照组患者给予尼莫地平片,观察组在对照组的基础上给予尼麦角林片,经过3个月的治疗后比较2组患者的临床疗效及不良反应,观察2组患者治疗前后的Barthel指数、MMSE评分、E2、HIF-1α水平。结果 治疗前2组患者Barthel指数、MMSE评分、E2、HIF-1α水平无明显差异(P>0.05); 治疗3个月后2组患者的E2水平、Barthel指数、MMSE评分均显著升高(P<0.05),但观察组显著高于对照组(P<0.05); HIF-1α水平显著下降(P<0.05),且观察组显著低于对照组(P<0.05)。观察组与对照组的总有效率分别为94.20%及82.61%,2组比较差异显著(χ2=4.520,P=0.033); 两组不良反应发生率分别为7.250%和5.80%,2组比较无明显差异(χ2=0.120,P=0.730)。结论 尼莫地平联合尼麦角林治疗阿尔茨海默病具有良好的临床疗效,能改善患者的认知功能障碍,有效的缓解脑细胞的缺血缺氧症状,且安全性较高。
Abstract:
ObjectiveTo observe the clinical effect of nimodipine combined with niergoline on patients with Alzheimer's disease and its effect on the serum level of E2,HIF-1α.Methods 138 AD patients who were hospitalized in our hospital from June 2015 to March 2018 were selected. According to the method of random digital table, it was divided into control group and observation group.The patients in the control group were treated with nimodipine tablets, and the patients in the observation group were given niergoline tablets on the basis of the control group. After 3 months of treatment, the clinical efficacy and adverse reactions of the two groups were compared. Barthel index and MMSE score were measured before and after treatment.Results Before treatment there was no significant difference in Barthel index and MMSE score between the two groups(P>0.05). After 3 months of treatment the level of E2 and the scores of Barthel index and MMSE were significantly increased in both groups(P<0.05), and the level of E2 and the scores of Barthel index and MMSE were significantly higher in the observation group than those in the control group(P<0.05). After 3 months of treatment The HIF-1α level decreased significantly(P<0.05), and The HIF-1α level of the observation group was significantly lower than that of the control group(P<0.05).The total effective rates of the observation group and the control group were 94.20% and 82.61% respectively, and there was a significant difference between the two groups(χ2=4.520,P=0. 033).The incidence of adverse reactions in the two groups was 7.250% and 5.80% respectively, and there was no significant difference between the two groups(χ2=0.120,P=0.730).Conclusion Nimodipine combined with niergoline had a good clinical effect on Alzheimer's disease. It could improve the cognitive function of the patients and relieve the ischemic and hypoxic symptoms of brain cells.

参考文献/References:

[1] 公维军.慢性脑低灌注与认知功能障碍的关系[J].中华老年心脑血管病杂志,2017,19(12):1333-1335.
[2] 张翠云,卢祖能,章军建,等.盐酸多奈哌齐联合尼莫地平在改善血管性痴呆患者认知功能和自理能力中的作用[J].中国临床保健杂志,2016,19(3):236-239.
[3] 张春荣,于怀成.盐酸多奈哌齐联合尼麦角林治疗老年性痴呆43例[J].医药导报,2013,32(1):48-49.
[4] 王建伟,金香兰,刘雪梅,等.益肾化浊法对慢性脑缺血血管性痴呆大鼠脑组织海马HIF-1α和VEGF表达的影响[J].环球中医药,2015,8(4):403-406.
[5] 代晓杰,董素娟,贾颐.美金刚对老年血管性痴呆的疗效及对血清VEGF和E2的影响[J].西南国防医药,2016,26(1):20-22.
[6] 孙其伟,李跃华.老年性痴呆的诊断及鉴别诊断[J].中国临床医生杂志,2010,38(8):13-15.
[7] 龙淼.早期康复操对脑卒中偏瘫患者Barthel指数和Fuel-Meyer运动功能及生存质量影响[J].中国全科医学,2017,20(S2):322-323.
[8] 孙亮,张新卿,汤哲,等.血管性痴呆患者发病前后精神状态检查量表评分变化及其预测因子的分析[J].中国脑血管病杂志,2012,09(3):132-135.
[9] Jia J,Wei C,Liang J,et al.The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease:A multicentre, randomized, double-blind, placebo-controlled trial[J].Alzheimers Dement,2015,12(2):89-99.
[10] Huai YP,Dong YH,Xu J,et al.L-3-n-butylphthalide protects against vascular dementia via activation of the Akt kinase pathway[J].Neural Regeneration Research,2013,8(19):1733-1742.
[11] 颜永刚,王红艳,尹立敏,等.太白洋参不同溶剂提取物对老年性痴呆模型大鼠TNF-α,CRP,5-HT,AChE的影响[J].中成药,2016,38(4):908-911.
[12] 叶民.阿尔茨海默病病因及发病机制研究进展[J].实用老年医学,2017,31(5):402-406.
[13] 戴伦.高血压与老年性痴呆的关系[J].中华高血压杂志,2016,24(10):915-922.
[14] 赵小亚,朱庆,朱军,等.艾司西酞普兰联合尼莫地平,多奈哌齐治疗血管性痴呆]伴发抑郁的临床效果[J].实用临床医药杂志,2016,20(21):21-23.
[15] 马玲梅.尼莫地平联合多奈哌齐治疗老年痴呆的效果观察[J].中西医结合心脑血管病杂志,2016,14(11):1298-1300.
[16] 杨廷海,张丽萍,殷建保,等.脉络宁口服液联合尼麦角林治疗血管性痴呆临床研究[J].中西医结合心脑血管病杂志,2017,15(16):2053-2055.
[17] 李运刚,李建军,周雪梅.老年血管性痴呆患者血清HIF-1α,VEGF的变化及相关性研究[J].脑与神经疾病杂志,2016,24(11):698-700.
[18] 陈妍.性激素水平与老年期痴呆的研究进展[J].神经疾病与精神卫生,2010,10(1):97-99.
[19] 周建军,张馨,徐运.雌激素对老年性痴呆的防治作用及其分子机制的新进展[J].国际神经病学神经外科学杂志,2005,32(1):99-102.
[20] 王莹莹,李玉凤.石杉碱甲对老年男性血管性痴呆患者雌激素水平和认知功能的影响[J].临床合理用药杂志,2016,9(21):6-8.

更新日期/Last Update: 2019-06-25